Welcome to our dedicated page for Nuvectis Pharma news (Ticker: NVCT), a resource for investors and traders seeking the latest updates and insights on Nuvectis Pharma stock.
Nuvectis Pharma, Inc. reports developments as a clinical-stage biopharmaceutical company focused on precision medicines for serious oncology indications. Company news centers on NXP900, an oral small-molecule inhibitor of the SRC Family of Kinases, including SRC and YES1, and on clinical and preclinical work in genetically or molecularly defined cancer settings.
Recurring updates include financial results, business highlights, clinical program progress, AACR and other oncology conference presentations, pharmacokinetic and pharmacodynamic findings, drug-drug interaction data, and combination-therapy research in non-small cell lung cancer and other advanced solid tumors. News also covers capital resources and financing activity tied to development operations.
Nuvectis Pharma reported financial results for 2021, marking a significant year for the company. It completed an initial public offering in February 2022, raising $16.0 million in gross proceeds. Nuvectis initiated a Phase 1a clinical trial for its drug candidate NXP800 and reported promising preclinical data for NXP900, targeting triple-negative breast cancer. The company managed cash prudently, with $5.7 million in cash and equivalents by the end of 2021, and an operating loss of $12.9 million for the year.
Nuvectis Pharma, Inc. (NASDAQ: NVCT) announced that its drug candidates NXP800 and NXP900 will be presented at the 2022 American Association for Cancer Research Meeting. NXP800, an orally active HSF1 pathway inhibitor, will have an oral presentation on April 10, 2022. NXP900, a preclinical Src kinase inhibitor, will be featured in a poster presentation on April 12, 2022. NXP800 is currently in a Phase 1 clinical study, while NXP900 is undergoing IND-enabling studies to target various cancers. Both candidates aim to address serious conditions of unmet medical need in oncology.
Nuvectis Pharma announced that CEO Ron Bentsur will participate in a fireside chat at the 34th Annual Roth Conference on March 15, 2022, at 2:30 PM PT (5:30 PM ET). The conference will showcase the company's focus on innovative precision medicines for oncology. Nuvectis is developing NXP800, a clinical-stage HSF1-pathway inhibitor, and NXP900, a SRC/YES1 kinase inhibitor currently in IND-enabling pre-clinical testing. More details can be found on their website.
Nuvectis Pharma (NASDAQ: NVCT) announced promising findings published in Cancer Research, showcasing the potent activity of NXP900, a selective SRC/YES1 kinase inhibitor, particularly in Triple Negative Breast Cancer (TNBC) models with Integrin-Linked Kinase (ILK) loss. The study confirms NXP900's superior efficacy compared to bosutinib and highlights its potential to address significant unmet medical needs in breast cancer treatment. Ongoing preclinical studies aim to identify additional cancers and complete IND-enabling studies in 2022.
Nuvectis Pharma, Inc. (Nasdaq: NVCT) has successfully closed its upsized initial public offering, selling 3,200,000 shares at $5.00 each, raising gross proceeds of $16 million. The funds will support the Phase 1/2 development of NXP800, IND-enabling studies for NXP900, and general corporate purposes, including hiring and capital expenditures. H.C. Wainwright & Co. managed the offering. The related registration statements became effective on February 4, 2022. Nuvectis focuses on innovative precision medicines for oncology, with NXP800 currently in clinical trials and NXP900 in preclinical development.
Nuvectis Pharma, Inc. (Nasdaq: NVCT) has announced the pricing of its initial public offering (IPO) of 3,200,000 shares at $5.00 each, aiming for gross proceeds of $16 million. The underwriter, H.C. Wainwright & Co., has an option to purchase an additional 480,000 shares. Proceeds will be allocated to the Phase 1/2 development of NXP800, IND-enabling studies for NXP900, and other corporate needs. Trading on the Nasdaq begins today with the offering expected to close on February 8, 2022, subject to customary closing conditions.